231 related articles for article (PubMed ID: 10097145)
1. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
Baluna R; Rizo J; Gordon BE; Ghetie V; Vitetta ES
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3957-62. PubMed ID: 10097145
[TBL] [Abstract][Full Text] [Related]
2. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
[TBL] [Abstract][Full Text] [Related]
3. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome.
Kuan CT; Pai LH; Pastan I
Clin Cancer Res; 1995 Dec; 1(12):1589-94. PubMed ID: 9815960
[TBL] [Abstract][Full Text] [Related]
4. Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL.
Pitcher C; Roberts L; Fawell S; Zdanovsky AG; FitzGerald DJ; Lord JM
Bioconjug Chem; 1995; 6(5):624-9. PubMed ID: 8974463
[TBL] [Abstract][Full Text] [Related]
5. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
Siegall CB; Liggitt D; Chace D; Mixan B; Sugai J; Davidson T; Steinitz M
Clin Cancer Res; 1997 Mar; 3(3):339-45. PubMed ID: 9815690
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Liu XY; Pop LM; Schindler J; Vitetta ES
MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
[TBL] [Abstract][Full Text] [Related]
7. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers.
Lindstrom AL; Erlandsen SL; Kersey JH; Pennell CA
Blood; 1997 Sep; 90(6):2323-34. PubMed ID: 9310483
[TBL] [Abstract][Full Text] [Related]
8. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Soler-RodrÃguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
[TBL] [Abstract][Full Text] [Related]
9. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice.
Smallshaw JE; Ghetie V; Rizo J; Fulmer JR; Trahan LL; Ghetie MA; Vitetta ES
Nat Biotechnol; 2003 Apr; 21(4):387-91. PubMed ID: 12627168
[TBL] [Abstract][Full Text] [Related]
10. An in vivo model to study immunotoxin-induced vascular leak in human tissue.
Baluna R; Vitetta ES
J Immunother; 1999 Jan; 22(1):41-7. PubMed ID: 9924698
[TBL] [Abstract][Full Text] [Related]
11. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
12. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
[TBL] [Abstract][Full Text] [Related]
13. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.
Kreitman RJ; Pastan I
Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):29-37. PubMed ID: 7717988
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
Debinski W; Pastan I
Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
16. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
17. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
19. Design of a modular immunotoxin connected by polyionic adapter peptides.
Kleinschmidt M; Rudolph R; Lilie H
J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
[TBL] [Abstract][Full Text] [Related]
20. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
